Cargando…
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies
SIMPLE SUMMARY: The management of primary tumors in metastatic colorectal cancer patients is still a broad and controversial scenario. While in the case of symptomatic primary tumors, the indication for surgery is a need rather than a choice, in the case of asymptomatic patients, literature data are...
Autores principales: | Fanotto, Valentina, Rossini, Daniele, Casagrande, Mariaelena, Bergamo, Francesca, Spagnoletti, Andrea, Santini, Daniele, Antoniotti, Carlotta, Cupini, Samanta, Daniel, Francesca, Nasca, Vincenzo, Vetere, Guglielmo, Zaniboni, Alberto, Borelli, Beatrice, Carullo, Martina, Conca, Veronica, Passardi, Alessandro, Tamburini, Emiliano, Masi, Gianluca, Pella, Nicoletta, Cremolini, Chiara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670103/ https://www.ncbi.nlm.nih.gov/pubmed/38001711 http://dx.doi.org/10.3390/cancers15225451 |
Ejemplares similares
-
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials
por: Dell’Aquila, E., et al.
Publicado: (2022) -
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, Daniele, et al.
Publicado: (2020) -
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
por: Borelli, B., et al.
Publicado: (2021) -
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, D., et al.
Publicado: (2021) -
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)